UNSPSC 51102824: Benzalkonium chloride/chloroxylenol/hydrocortisone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT250. This VA Drug Class (OT250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OTIC.

UNSPSC 51102824 Benzalkonium chloride/chloroxylenol/hydrocortisone is a Commodity code that in recent state and local procurement activity captures the sourcing of pharmaceutical products and medical supplies, though the recent opportunities tagged to it diverge significantly from the code's nominal scope and instead reflect broader health-system purchasing across naloxone, emergency response supplies, and generic pharmaceuticals through cooperative agreements. State and local governments buy under this code primarily through health departments, fire-rescue divisions, and pharmacy benefit programs seeking to stock formulary items, over-the-counter products, and emergency medical supplies for public-health and emergency-response missions. Issuing bodies include county health departments, municipal fire services, state health and human services commissions, and cooperative purchasing alliances administering multi-state pharmaceutical contracts. The code sees activity across multiple regions, with recent solicitations originating in Florida, Texas, Minnesota (serving multiple states including Oregon), and municipal procurement in Tampa.

Representative recent opportunities include Seminole County, Florida's invitation for bid (IFB 60459723LAS) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries due by July 26, 2023; the City of Tampa's sealed-bid solicitation (26P00145) for 169 line items of medical and first aid supplies intended for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000.00 and a response deadline of March 13, 2026, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount; the Minnesota Multistate Cooperative Purchasing Alliance's request for proposal (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, with proposals due March 26, 2026; and the Texas Health and Human Services Commission's request for information (HHS0017013) exploring direct-to-manufacturer prescription programs, posted April 3, 2026. The code shows limited recent activity with clear alignment to its nominal chemical composition—the tagged opportunities reflect broader health-system procurement that includes but is not limited to the specific active ingredients named in the code.